Form 8-K - Current report:
SEC Accession No. 0001564590-21-014003
Filing Date
2021-03-18
Accepted
2021-03-18 07:00:33
Documents
14
Period of Report
2021-03-18
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K stro-8k_20210318.htm   iXBRL 8-K 36052
2 EX-99.1 stro-ex991_7.htm EX-99.1 187819
3 GRAPHIC gpco3flm4cqz000001.jpg GRAPHIC 10548
  Complete submission text file 0001564590-21-014003.txt   387163

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA stro-20210318.xsd EX-101.SCH 5776
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE stro-20210318_lab.xml EX-101.LAB 20227
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE stro-20210318_pre.xml EX-101.PRE 12084
7 EXTRACTED XBRL INSTANCE DOCUMENT stro-8k_20210318_htm.xml XML 3679
Mailing Address 310 UTAH AVE., SUITE 150 SOUTH SAN FRANCISCO CA 94080
Business Address 310 UTAH AVE., SUITE 150 SOUTH SAN FRANCISCO CA 94080 650-392-8412
SUTRO BIOPHARMA, INC. (Filer) CIK: 0001382101 (see all company filings)

EIN.: 452441988 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38662 | Film No.: 21753052
SIC: 2836 Biological Products, (No Diagnostic Substances)